Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods by Francisco D. C. Guerra Liberal et al.
	  	   1	  
Comparative analysis of eleven different radioisotopes for palliative 
treatment of bone metastases by computational methods 
Francisco D. C. Guerra Liberala, Adriana Alexandre S. Tavaresb and João Manuel R. S. Tavaresc 
Instituto de Engenharia Mecânica e Gestão Industrial, Faculdade de Engenharia, Universidade do 
Porto, Rua Dr. Roberto Frias s/n, 4200-465 Porto, Portugal 
a meb12020@fe.up.pt 
b adriana_tavares@msn.com 
c tavares@fe.up.pt 
(Corresponding author) 
  
	  	   2	  
ABSTRACT: 
Purpose: Throughout the years, the palliative treatment of bone metastases using bone seeking radiotracers has 
been part of the therapeutic resources used in oncology, but the choice of which bone seeking agent to use is 
not consensual across sites and limited data is available comparing the characteristics of each radioisotope. 
Computational simulation is a simple and practical method to study and to compare a variety of radioisotopes 
for different medical applications, including the palliative treatment of bone metastases. This study aims to 
evaluate and compare eleven different radioisotopes currently in use or under research for the palliative 
treatment of bone metastases using computational methods.   
Methods: Computational models were used to estimate the percentage of deoxyribonucleic acid ( DNA)  
damage (fast Monte Carlo damage algorithm), the probability of correct DNA repair (Monte Carlo excision 
repair algorithm) and the radiation-induced cellular effects (Virtual Cell Radiobiology algorithm) post-
irradiation with selected particles emitted by Phosphorus-32 (32P), Strontium-89 (89Sr), Yttrium-90 (90Y), 
Tin-117 (117mSn), Samarium-153 (153Sm), Holmium-166 (166Ho), Thulium-170 (170Tm), Lutetium-177 
(177Lu), Rhenium-186 (186Re), Rhenium-188 (188Re) and Radium-223 (223Ra). 
Results: 223Ra alpha particles, 177Lu beta minus particles and 170Tm beta minus particles induced the 
highest cell death of all investigated particles and radioisotopes. The cell survival fraction measured post 
irradiation with beta minus particles emitted by 89Sr and 153Sm, two of the most frequently used radionuclides in 
the palliative treatment of bone metastases in clinical routine practice, was higher than 177Lu beta minus 
particles and 223Ra alpha particles. 
Conclusions: 223Ra and 177Lu hold the highest potential for palliative treatment of bone metastases of all 
radioisotopes compared in this study. Data reported here may prompt future in vitro and in vivo experiments 
comparing different radionuclides for palliative treatment of bone metastases, raise the need for the 
careful rethinking of the current widespread clinical use of 89Sr and 153Sm, and perhaps strengthen the use of 
223Ra and 177Lu in the palliative treatment of bone metastases. 
 
Key words: Computational simulation, Deoxyribonucleic acid, Radium-223, Lutetium-177  
  
	  	   3	  
I. INTRODUCTION 
Cancer is a major public health concern, and it is associated with significant morbidity and mortality. 
In 2012, approximately 14 million new cases were diagnosed, and 8 million cancer-related deaths occurred. 
Prostate cancer is the second most common cancer in men worldwide.1 A large percentage of patients with 
prostate cancer (65-75%) develop bone metastasis2–4, which often leads to severe pain, hypercalcemia, lack of 
mobility and depression that adversely affect these patients’ life quality.5 There are several therapeutic 
approaches targeting bone metastases and its associated effects, including the use of analgesics, external beam 
radiotherapy and radionuclide systemic therapy. The latter, systemic palliative targeted-therapy with suitable 
radiotracers, has emerged as a particularly appealing and efficient treatment modality for patients with 
multiple skeletal metastases.3,6–8 
Over the years, efforts were made to identify radionuclides with improved physical properties for use in 
palliative care of metastatic bone pain, as well as to develop better bone seeking agents to be used for 
radiolabelling with promising radionuclides. A major challenge associated with the palliative treatment of bone 
pain using selective radiotracers is to deliver an adequate dose of ionizing radiation to the bone lesion, while 
minimizing the dose to healthy bone sites and adjacent tissues. The radionuclide emitted particles should have 
an energy and tissue penetration range compatible with the volume of the lesion to be irradiated 2,9, given that 
both the energy and the penetrating range of a radionuclide emitted particle significantly contribute to the 
therapy efficacy.10 Therefore, studying the effects of particulate radiation at the cellular level is of interest to 
determine the suitability of a given radionuclide for target-tumor radiotherapy. There are essentially three main 
types of radioactive particles that are of interest for target-tumor radiotherapy: beta minus (β-) particles, alpha 
(α) particles and Auger electrons. The β- particles present an average range of few millimeters, which may 
result in neighboring cells irradiation due to crossfire. By contrast, α particles have a typical penetration range 
of less than 100 µm.11 Auger electrons are low energy electrons (typical energies around 20-100 KeV) and 
have short penetration ranges of few nanometers to micrometers. Owing to their short penetration range, 
systemic target-tumor radiotherapy with Auger electrons often yields lower toxicity to the bone marrow in 
comparison to β- particles.12 In addition to the physical properties of different radionuclides for target-tumor 
therapy, other characteristics should be taken into consideration while searching for the ideal radiotracer for 
palliative treatment of bone metastases. For example, the radionuclide production costs and feasibility should 
be determined, and consideration should be given on whether its properties are amenable for radiochemistry 
procedures.8 It is also important that the radionuclide to be used for palliative treatment of bone metastases 
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allows for in vivo imaging, in order to assist with the determination of the suitable therapeutic dose to be used 
and to facilitate treatment monitoring.6,13 
In recent years, several reports have been published describing the use of multiple radionuclides in the 
context to palliative treatment of bone metastases. Radioisotopes investigated for this application included: 
Phosphorus-32 (32P), Strontium-89 (89Sr), Yttrium-90 (90Y), Tin-117m (117mSn), Samarium-153 (153Sm), 
Holmium-166 (166Ho), Thulium-170 (170Tm), Lutetium-177 (177Lu), Rhenium-186 (186Re), Rhenium-188 
(188Re) and Radium-223 (223Ra) 2,5,6,9–11,14–32. The main physical characteristics of these radionuclides are 
presented in Table 1. 
 
Table 1: Summary of main physical properties of different radionuclides in clinical used or under research for 
palliative treatment of bone metastases. 
Radionuclide 
Emission 
Type 
E (MeV) (%) 
Eγ (KeV) 
(%) 
T1/2  (days) 
Tissue penetration 
 range (mm) 
References  
32P β
- 0.6955    (100) - 14.3 8.0 5,14,33 
89Sr β
- 0.5846    (99.99) 909 (0.1) 50.5 6.7 5,14,33 
90Y β
- 0.2670    (99.98) - 2.67 2.7 14,33 
117mSn Auger 0.1268    (64.8) 159 (86) 13.6
 0.3 5,14,33 
153Sm β
- 0.2253    (48.2) 103 (28) 1.93 3.4 5,14,33 
166Ho β
- 0.6511    (50.5) 81 (6.4) 1.12 8.6 14,33 
170Tm β
- 0.3231    (81.6) 84 (3.3) 127.8 5 26,33 
177Lu β
- 0.1494    (79.3) 211 (11) 6.2 1.8 14,33 
186Re β
- 0.3596    (70.9) 137 (9) 3.8 4.7 5,14,33 
188Re β
- 2.1204    (71.1) 155 (15) 0.7 2.4 5,17,33 
223Ra α 5.71581  (45.6) 154 (5.6) 11.4
 0.1 5,13,33 
Legend: T1/2  (days) – radioisotope half-life in days; E (MeV) (%) – particle energy and respective decay abundance 
shown in parentheses; Eγ (KeV) (%) – gamma ray energy and respective abundance in total energy emission shown in 
parentheses; Tissue penetration range (mm) – maximum tissue penetration shown in millimeters. 
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The 32P was the first radioisotope to be evaluated for palliative treatment of bone metastases and its 
first clinical use dates back to 1941.34 In the late 1980s, 186Re was identified as a potential agent for palliative 
treatment of bone metastases and it is currently being used in phase III clinical trials.35 Presently, one of the 
most commonly used radionuclides for palliative treatment of bone metastases in routine clinical practice is 
153Sm, which was approved by the Food and Drug Administration (FDA) for clinical use in 1997.32 89Sr is 
also currently used in the clinical setting for alleviation of bone pain and it was approved by the FDA for 
clinical use in 1993.26 Recently, a significant amount of work has been carried out using 223Ra, a promising 
therapeutic agent for palliative treatment of bone metastases, in order to take advantage of the low tissue 
penetration range associated with its emitted α particles. In clinical studies, 223Ra has demonstrated a highly 
significant improvement on patient overall survival, with mild side effects owing to its localized tissue 
penetration (2-10 cells). Its clinical use was approved by the FDA in 2013.11 Another promising radionuclide 
recently proposed for palliative treatment of bone metastasis was 177Lu, due to its appealing physical 
characteristics, in particular its half-life of 6.73 days, gamma ray emission of 113keV (6.4%) and 208 keV 
(10.4%) and tissue penetration of 1.8 mm.26 Moreover, both 188Re and 117mSn are currently being investigated 
as potential agents for palliative treatment of bone metastases and are being used in different phases of 
clinical trials.5,14,36,37 Several studies have also been undertaken to study the potential of 90Y, 166Ho and 170Tm 
for palliative treatment of bone metastases.18,26,38,39 
Despite the increasing availability of radionuclides for palliative treatment of bone metastases26,35, the 
choice of which therapeutic agent to use is not consensual across sites and no standardization or guideline 
exists to assist with this choice. This may be due to the limited data available comparing the advantages and 
disadvantages of each radioisotope, as well as assessing all radioisotopes in the same test conditions. 
Computational simulation is a simple and practical method to study and to compare a variety of radioisotopes 
for different medical applications, including the palliative treatment of bone metastases, under the same 
research conditions. This study aims to use computational methods to evaluate and compare different 
radioisotopes currently in use or under research for the palliative treatment of bone metastases. In particular, 
the data reported here will focus on the bone metastases from the prostate carcinoma, given this is one of the 
most common types of cancer in men worldwide and the majority of these patients develop bone metastases. 
 
II. METHODS 
Three different computational simulators were used to investigate the therapeutic potential of the 
	  	   6	  
following radioisotopes: 32P, 89Sr, 90Y, 117mSn, 153Sm, 166Ho, 170Tm, 177Lu, 186Re, 188Re and 223Ra. The 
sections below explain the main principles of these simulators and points out the key input parameters 
adopted. 
 
II.A. Fast Monte Carlo damage formation simulator 
The Monte Carlo damage simulation (MCDS) algorithm can be used to predict the types of 
deoxyribonucleic acid (DNA) damage and their yield after irradiation. This method allows for rapid 
collection of a large data set with multiple irradiation scenarios. The model generates a number of damage 
configurations expected within the DNA of one cell, where the algorithm processes information in two main 
steps: first, it randomly distributes, in a DNA segment, the expected amount of damage produced in a cell; 
then, it subdivides the distribution of damage in that particular DNA segment. Studies have shown that the 
number and spatial distribution of t h e  damage configurations predicted by the MCDS algorithm are in 
reasonable agreement with those predicted by more complex track-structure simulations40, indicating the 
MCDS simulator i s  a  useful tool for studies aiming at comparing different radioisotopes used for target 
tumor radiotherapy. A detailed description of the MCDS model as well as additional discussions about the 
validity and limitations this method are presented in, for example, references 40 and 41. 
The classification scheme used by the MCDS to categorize DNA damages is based on the 
classification parameters proposed by Nikjoo et al., and it comprises essentially: (a) no damage, (b) single-
strand breaks (SSBs), (c) two strand breaks on the same strand (SSB+), (d) two or more strand breaks on 
opposite strands separated by at least 10 base pairs (2SSB), (e) two strand breaks on opposite strands with a 
separation not greater than 10 base pairs [double-strand breaks (DSBs)], (f) DSB accompanied by one (or 
more) additional strand breaks within a 10 base pair separation (DSB+), and (g) more than one DSB, whether 
within the 10 base pair separation or further apart (DSB++). For further details, see references 42 and 43. 
 
II.B. Fast Monte Carlo excision repair simulator 
The Monte Carlo excision repair (MCER) algorithm can be used to calculate the formation and repair 
of DNA damages and to predict repair outcomes such as correct repair, repair with a mutation and conversion 
into a DSB.44 The MCER algorithm starts by using the MCDS algorithm to generate a random number of 
damage configurations expected within the DNA of one cell. Subsequently, the MCDS-generated damage 
configurations are superimposed over a predetermined nucleotide sequence or a random nucleotide sequence. 
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Then, the MCER model is used to simulate the repair, misrepair and aborted excision repair of damage within 
the entire genome or within a specific region of the DNA. The lesions forming a cluster are removed 
sequentially through repeated rounds of excision repair. 
The majority of DNA oxidative damage, including modified apurinic/apyrimidinic converted into 
strand breaks, requires repair by base excision repair (BER). Two different types of BER processes have 
been observed in eukaryotic and prokaryotic cells: (1) e xcision and replacement of a single nucleotide, 
known as short-patch BER (SP-BER), which occurs in most cases; and (2) replacement of 2–13 
nucleotides, known as long-patch BER (LP-BER). Another enzymatically distinct repair pathway is 
nucleotide excision repair (NER). The NER, observed in eukaryotic cells, substitutes oligonucleotide 
fragments of 24–32 nucleotides in length.44 Results from this simulator are outputted as simplified repair 
scenarios, due to the current uncertainties associated with the processing of radiation-induced damage by the 
BER and NER pathways.  the simplified repair scenarios modelled and outputted by MCER, studies by Semenenko 
and Stewart have demonstrated that the results obtained by this simulator correlate well with in vitro results 
obtained using cell cultures.45 A detailed description of the MCER algorithm, as well as additional 
discussions on the validity and limitations of the model can be found in references 40 and 44. 
 
II.C. Virtual cell radiobiology simulator 
The radiation-induced damage can be lethal or can be slowly repaired via enzymatic repair and 
misrepair, which then determines the fate of the irradiated cell. The cell cycle kinetics can influence and/or be 
influenced by the kinetics of damage processing; and damages to the DNA are often a trigger for apoptosis, 
although cell membrane damages can also induce apoptosis.44,46 Radiobiological models have been 
developed to describe the dose-response association, the process of damage production and the key repair 
mechanisms. These models often correlate the dose rate with the cell response to irradiation. Some of the 
existing models include the repair-misrepair (RMR) model, lethal-potentially lethal (LPL) model and two-
lesion kinetics (TLK).46 The main disadvantage of the LPL model is its inability to correlate the biochemical 
processes of DSB with the cell death. The RMR and linear quadratic models also share this limitation. 
Conversely, the TLK model carries out an improved correlation between the biochemical processes of DSB 
and the cell death by subdividing DSB into simple or complex DSBs. This subdivision is important since 
simple and complex DSBs have different repair characteristics.47 Therefore, all simulations carried out 
here using the Virtual Cell (VC) radiobiology simulator were performed using the TLK model. Further 
	  	   8	  
details on this computational simulator can be found at: http://faculty.washington.edu/trawets/vc.  
 
II.D. Simulated parameters 
For each investigated radioisotope, only the most abundantly emitted radioactive particles were 
evaluated using the MCDS and MCER simulators. The general input details used for simulations with the 
MCDS model were as follows: initial cell number of 1000 and DMSO concentration of 0. The MCER input 
conditions are defined as follows: inhibition distance of 3 base pairs; probability of choosing a lesion from 
the first stand break of 0.5; polymerase error rate for SP-BER and LP-BER of 1.0-4 and 1.0-6, respectively; 
probability of incorrect insertion of opposite base lost of 0.75; and probability of incorrect insertion of 
opposite damaged base of 0.75.  
In the input file for the VC simulator, the cell cycle time (Tc) and the cell potential doubling time (Tpot) 
values were adjusted to modeling two different cell phenotypes: normal prostate cells (Tc = 48 h and Tpot= 
500 days) and metastatic prostate cells (Tc = 48 h and Tpot = 54 days).
48 The number of DSBs and the 
percentage of complex DSBs were obtained from the MCDS simulator. These results were then applied as 
input parameters for the TLK model used in the VC simulator. Irradiation periods of 2, 24, 48, 120 and 240 
h (TCUT—time allowed for repair after exposure), with total absorbed doses of 0 .1, 0.5, 1, 2, 5 and 8 
Gy were studied using t h e  V C  simulator. Other parameters used in the VC simulator, specified in the TLK 
model input file, included: (1) DRM (damage repair model) = TLK, (2) CKM (cell kinetics model) = QECK 
(quasi-exponential cell kinetics model); (3) DNA (cell DNA content) = 5.667D+09 base pair; (4) DSB 
(endogenous) = 4.3349×10-03 Gy-1 cell-1; (5) RHT (repair half-time) = XXX, XXX = 0.25, 9 h (simple DSBs 
are repaired faster than complex DSBs); (6) A0 (probability of  correct repair) = AAA, AAA = 0.95, 0.25 
(simple DSBs are repaired more accurately than complex DSBs); (7) ETA (pairwise damage interaction 
rate) = 2.5×10-04 h-1; (8) PHI (probability of a misrejoined DSB being lethal) = 0.005; (9) GAM (fraction 
of binary-misrepaired damages that are lethal) = 0.25; (10) N0 (initial number of cells) = 1000; (11) KAP 
(peak cell density) = 1.0D+38 cells/cm3; (12) VOL (tissue volume) =  1 cm3; (13) FRDL (fraction of 
residual that is lethal damage) = 0.5; (14) ACUT (absolute residual damage cutoff) = 1.0E−09 expected 
number of DNA damages per cell; (15) BGDR (average background absorbed dose rate on planet Earth) = 
2.73748×10-07 Gy/h; (16) DCUT (dose cutoff) = 0.01 Gy; (17) STOL (step-size tolerance) = 0.01 Gy/h; (18) 
SAD (scaled absorbed dose) = RX1, RX1 = 0.1, 0.5, 1, 2, 5 and 8 Gy; (19) GF [growth fraction, if 0 (zero) 
all cells are quiescent, if 1 (one) all cells are cycling and if 0.5 the cell population is heterogeneous] = 0, 
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0.5, 1.49 
 
II.E. Statistical analysis 
The MCDS results are expressed as a percentage of damage. The MCER results are expressed as a 
probability of repair or number of cell cycles. The VC values are expressed as survival fraction or the 
number of surviving cells. The statistical significance was determined using ANOVA (p < 0.01). 
 
III. RESULTS 
III.A. MCDS and MCER results 
Figs. 1 and 2 present the radiation-induced DNA damages obtained post-irradiation with different 
radioactive particles, emitted by selected radioisotopes currently in use or under research for palliative 
treatment of bone metastases. The probability of correct repair, repair with a mutation and conversion into a 
DSB, and the number of repair cycles are presented in Figs. 3 and 4. Results obtained using the MCDS 
and MCER algorithms showed that 223Ra α particles were able to induce the highest amount of DNA 
damages of all investigated particles, having the lowest probability of correct repair of damages and 
highest probability of the repair processes to induce DSB. 
 
Figure 1: DNA damage results obtained using the MCDS simulator. (A) Percentage of total DNA radioinduced 
SSB after irradiation; (B) Percentage of two different types of complex SSB; (C) Fraction of complex SSB 
DNA damages after irradiation; (D) Percentage of total DNA radioinduced DSB after irradiation; (E) Percentage 
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of two different types of complex DSB, (F) Fraction of complex DSB DNA damages after irradiation.   
	  
Figure 2: Ranking order of the MCDS simulator results for different radionuclides. Data organized from the 
highest to the lowest measured values. 
	  
 
Figure 3: DNA damage repair results obtained using the MCER simulator. Probability (A) of correct repair (p 
COR), (B) repair with mutation (p MUT), (C) conversion to DSB (p DSB) of DNA SSB and (D) average 
number of repair cycles. 
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Figure 4: Ranking order of the MCER simulator results for different radionuclides. Data organized from the 
highest to the lowest measured values.  
 
III.B. VC simulator 
The cell survival fraction results obtained after irradiation with different radionuclides and particles are 
shown in Fig. 5. The estimated survival fraction rank order of all investigated particles was as follows: 166Ho 
β- particles, 186Re β- particles, 188Re β- particles > 89Sr β- particles > 32P β- particles > 90Y β- particles > 
117mSn electrons > 153Sm β- particles > 177Lu β- particles > 170Tm β- particles >> 223Ra α particles. 
Additionally, statistically significant differences were observed among the different irradiating agents (p 
< 0.0001 and p = 0.0053 ANOVA, with and without 223Ra data, respectively). 
 
	  	   12	  
	  
Figure 5: (A) Cell survival fraction estimated for all isotopes in different exposure scenarios. (B) Cell survival 
fraction for 153Sm and 89Sr, two of the most commonly used radionuclides for palliative treatment of bone 
metastases in clinical routine: and 170Tm and 177Lu. The two radionuclides investigated in this study that 
presented the lowest survival fraction among all β- emitters evaluated. 
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The 223Ra α particles, the 170Tm β- particles and the 177Lu β- particles had the lowest survival 
fraction of all investigated irradiating agents, as determined using the VC simulator. Detailed examination 
of the estimated number of surviving cells at different proliferation status for these 3 irradiating agents is 
presented in Figs. 6 and 7. The estimated number of normal prostate cells that survived irradiation when 
all cells were quiescent, when the cell population was heterogeneous (with quiescent cells and cells actively 
dividing/on cycle) and when all cells were actively dividing is presented in Figs. 6a-6c, respectively. The 
number of metastatic prostate cells that survive the irradiation when all cells are quiescent, when the cell 
population is heterogeneous and all cells are actively dividing is shown in Figs. 7a-7c, respectively. When all 
cells were quiescent, the estimated number of normal prostate surviving cells is similar to the estimated 
number of metastatic prostate cells that survive irradiation and seems to be independent from the cell kinetics 
(Figs. 6a and 7a). Conversely, for actively dividing cellular populations, it is possible to observe that there are 
fewer surviving cells in the normal prostate cell population than in the metastatic prostate cell population (Figs. 
6c and 7c). The estimated number of cells that survived a given irradiation scenario decrease in the following 
order: 177Lu β- particles > 170Tm β- particles > 223Ra α particles. Statistically significant differences were 
observed among these 3 different irradiating agents when normal prostate cells were quiescent, the cell 
population was heterogeneous and all cells were actively dividing (p<0.0001, ANOVA). Similar results 
were found for the metastatic prostate cells (p<0.0001, ANOVA).  
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Figure 6: Number of normal prostate cells that survive irradiation with different irradiating agents in a 
quiescent cell population (A), in a heterogeneous cell population (B), and in cells actively dividing (C). 
Simulated doses of 0.1, 0.5, 1, 2, 5 and 8 Gy and irradiation periods of 2, 24, 48, 120 and 240 h. 
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Figure 7: Number of metastatic prostate cells that survive irradiation with different irradiating agents in a 
quiescent cell population (A), in a heterogeneous cell population (B), and in cells actively dividing (C). 
Simulated doses of 0.1, 0.5, 1, 2, 5 and 8 Gy and irradiation periods of 2, 24, 48, 120 and 240 h. 
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IV. DISCUSSION AND CONCLUSION 
Here we report the use of different computational methods to evaluate multiple radioisotopes for the 
palliative treatment of bone metastases, specifically in the context of metastatic prostate tumors. In this 
analysis, we included radioisotopes currently used in the clinical practice or under research as potentially 
useful agents for treatment of palliative bone metastases. The biological effects resulting from irradiation with 
these radioisotopes, both at the DNA level and at the cellular level, were evaluated and compared. Our 
findings, obtained by means of three different computational simulators, indicated that the most promising 
agents for palliative treatment of bone metastases from prostate cancer are the 223Ra α particles, the 177Lu β- 
particles and the 170Tm β- particles. Other commonly used radioisotopes for palliative treatment of bone 
metastases, such as 89Sr, were found to be inferior in inducing lethal damages than 177Lu, 170Tm or 223Ra, 
with radiobiological properties similar to 32P. Overall data also suggested that 153Sm β- particles were 
superior at inducing cell death compared with 89Sr β- particles. 
The MCDS results showed that the percentage of SSB and DSB after irradiation were highest for 
223Ra α particles, followed by 177Lu β- particles. The same trend was observed for a percentage of 
complex SSB and DSB. Conversely, the probability of correct repair was low for these irradiating agents 
and the number of repair cycles was high for all the repair processes studied, regardless of the repair 
route (MCER results). A higher number of repair cell cycles has been correlated with prolonged repair 
times45,49, which correlates with increased percentage of complex damages. Previous studies have 
demonstrated that the complex damage repair by excision can lead to an increased number of DSBs.45,50 It is 
well known that DNA DSBs are frequently associated with apoptosis induction.41 The damage induced by 
223Ra α particles and 177Lu β- particles seem to have hampered the successful repair of the DNA by BER 
or NER, presenting a high probability for DSB formation and low probability for correct repair. 
Furthermore, the high number of DNA DSBs induced by the 223Ra α particles and 177Lu β- particles 
together with their high DNA SSB conversion to DSB may translate an increased probability of apoptosis 
induction for these three radioisotopes compared with the other investigated agents. In fact, data from the 
VC simulator estimated a low survival fraction for 223Ra α particles and 177Lu β- particles, suggesting 
these irradiating agents would be more promising in the killing of metastatic cells than the other 
investigated irradiating agents. Furthermore, the VC simulator estimated a low survival fraction for cells 
irradiated with 170Tm β- particles. Interestingly, the total number of DSB induced by DNA irradiation 
with 170Tm β- particles was in the low range, but the percentage of complex DSB was ranked together 
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with 177Lu β- particles, which supports for the importance of modelling the fraction of complex DSB 
when determining the radiation induced cell damages using radiobiological models. 
Detailed analysis of the cellular kinetics post-irradiation using 177Lu β- particles, 170Tm β- 
particles and 223Ra α particles showed that the cell response was dose- and radionuclide-dependent. For 
low dose TCUTs, virtually no differences were found between 170Tm β- particles and 177Lu β- particles. 
Conversely, for high TCUT values, irradiation with 170Tm β- particles resulted in a lower number of 
surviving cells than irradiation with 177Lu β- particles. This may be a result of differences in the physical 
half-life of 177Lu and 170Tm (6.2 and 127.8 days, respectively) that will contribute differently for 
dissimilar radiation fractioning.  
Data also showed that a larger number of metastatic cells survived irradiation when compared 
with normal prostatic cells, in particular, when all cells were actively dividing. This observation 
highlights the influence of cell proliferation rate on cell response to irradiation, where a faster cell cycle 
time means the cells were less radiosensitive. Due to its shorter doubling time (54 days versus 500 days 
for metastatic and normal cells, respectively), metastatic prostate cells were able to compensate 
radiation-induced damage by rapid cell duplication.  
223Ra α particle emission is an appealing strategy for the treatment of bone micrometastases, 
owing to the short tissue range penetration associated with these radioactive particles that can allow for 
a more circumscribed irradiation surface. Furthermore, typically α emitters induce less hematologic 
toxicity for a given bone surface dose than β- emitters.6,11,16 The high linear energy transfer of α particles 
has been associated with greater biological effectiveness than β- particles.6,11,16 Our findings using 
computational simulation indicated that 223Ra α particles induced significantly more DSBs and were 
more effective in inducing cell death than all the other particles. To date, the 223Ra-dicloride has been 
the only radiotracer identified for treatment of palliative bone metastasis with shown ability to increase 
patients’ life-expectancy.11,51 
Within the β- particle emitters investigated here, the 177Lu has the lowest tissue penetration range (1.8 
mm). A common concern associated with the use of β- particle emitters is related to its large tissue 
penetration range of several millimeters, which can result in energy deposition in neighboring, non-targeted 
cells, a phenomenon known as “crossfire” that may lead to bystander effects. With α particle emitters, due to 
their short tissue penetration range, the “crossfire” effect is not such a concern, but may require targeting 
virtually every cell within large size tumors and does not take advantage of the positive bystander effects.39 
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The short tissue penetration range of 177Lu β- particles is placed in the lowest end of the β- particle emitter’s 
tissue penetration range, minimizing the negative “crossfire” effects often associated with β- particle emitters; 
and it is higher than typical α particles allowing us to take advantage of the positive bystander effects that are 
not attainable with conventional α particles emitters. In addition, 177Lu low β- particle energy and intermediate 
physical half-life of 6.73 days allow for a constant dose rate in the target lesion sites.25 Here we found that 
177Lu β- particles induced the maximum number of DSB among all β- emitters studied radionuclides and was 
part of the top three most effective radionuclides to induce cell death. Data presented here together with the 
physical characteristics of 177Lu previously described, suggest that replacing the radionuclides 153Sm and 89Sr 
with 177Lu in the EDTMP complex would improve the potential for cell death in target tissue, while reducing 
the bone marrow toxicity due to the shorter tissue penetration range of 177Lu β- particles in comparison with 
153Sm and 89Sr β- particles. 
The long physical half-life of 170Tm (128.6 days) can be an advantage for this radiotracer distribution 
and storage compared with either 223Ra (11.4 days) or 177Lu (6.2 days).32 However, the physical half-life of 
a radioisotope and the dosing regimen adopted can have a considerable impact on cellular response to 
irradiation. For example, delivery of 90% of the total dose of radiation requires approximately 3.5 half-
lives of decay32, which will correspond to a time interval of approximately 64 weeks for 170Tm, 6 weeks 
for 223Ra and 3 weeks for 177Lu.32 This may explain the VC results presented here, where the number of 
cells surviving irradiation with 170Tm β- particles was lowest when the TCUT was highest, which 
highlights the importance of adjusting the therapeutic fractioning scheme to the chosen radionuclide. The 
longer time period required to deliver 90% of the radiation dose of 170Tm compared with 223Ra and 177Lu 
may be a disadvantage for patients with short life expectancy. 
The clinical outcomes of the palliative treatment of bone metastases using radiotracers can vary 
with the used radionuclide and radiotracer (see, Supplementary Table 1). Notwithstanding, previously 
published data has shown that the 223Ra α particles have an increased anti-tumor effect when compared 
with β- particles.6,16,28 This might explain recent data demonstrating that 223Ra was the first agent in its 
class to show an overall survival advantage in patients with bone metastases from prostate carcinomas.35 
In line with these observations, our in silico analysis showed a superiority of 223Ra α particles compared 
with the modelled β- particles. 
Computational methods allow for rapid and easy data collection. Nonetheless, some limitations have 
been pointed out, including modeling and evaluation based on current knowledge, which works as a 
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mechanistic process. Furthermore, the computational algorithms used in this study only model simple repair 
processes and exclude DSBs repair processes, such as homologous repair and non-homologous end 
joining (NHEJ) repair processes. Moreover, the used algorithms assume an optimal scenario of ionizing 
energy deposition directly into the DNA, scenario that often is challenging to achieve in vitro and in vivo 
due to inefficient radiotracer biodistribution processes. Notwithstanding, thus far, results from in silico 
testing using the VC simulator have been compared with data from a total of 23 in vitro datasets obtained using 
different cell types and exposure conditions. Results from that in silico versus in vitro comparison 
demonstrated that the simulated data obtained using the VC algorithm compared favorably with real-life 
measured data. Results from comparative tests against 23 published radiobiological datasets can be found at 
http://faculty.washington.edu/trawets/archive/index.html. Therefore, although validation of the used simulators 
has been carried out in selected irradiation scenarios and specific cellular populations40,47,50,52, indicating these 
methods can be useful as a first-line approach to large data sets to help planning subsequent in vitro and in vivo 
studies, the data presented here requires further validation by means of in vitro and in vivo studies to fully 
establish the therapeutic potential of the investigated radioisotopes in the context of palliative treatment of 
bone metastases. In particular, because the clinical outcome of a given therapeutic depends not only on the 
cellular response, but also on, for example, the individual patient differences in clinical conditions, patient 
preparedness, life expectancy, age and the existence of secondary tumors. Furthermore, aspects such as 
radiotracer biodistrubition, elimination and concentration in the biological target tissue in vivo would also 
impact therapeutic response. 
In conclusion, this study compared different irradiating agents using the same exposure conditions and 
controllable cell populations to clarify the quality of these radioisotopes for palliative treatment of bone 
metastases, specifically in the context of prostate cancer. Collected data allowed the ranking of eleven different 
radioisotopes in terms of ability to induce DNA damage and probability of damage repair. The top three agents 
able to induce the highest cellular damage and cell death were found to be the 177Lu β- particles, 170Tm β- 
particles and 223Ra α particles. 223Ra-dichloride is a particularly appealing approach for the treatment of 
bone metastases based on the data reported here, this radionuclide physical properties, suitable production 
methods and feasible logistics of distribution. Within the β- particle emitters investigated, 177Lu was the 
preferred one due to its estimated low survival fraction, together with its adequate half-life and physical 
properties for image acquisition. Although 170Tm β- particles may also represent an interesting therapeutic 
approach in the palliative treatment of bone metastases, its long half-life and low gamma ray emission yield 
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may be suboptimal for a rapid pain alleviation and therapy monitoring of cancer patients. Data presented here 
indicated that 89Sr and 153Sm, two of the most frequently used radionuclides in the palliative treatment of bone 
metastases in clinical routine practice, had modest effect on the cell survival fraction. Although in vitro and in 
vivo data are necessary to support our findings, the observations reported here may support for a careful 
rethinking of the widespread clinical use of 89Sr and 153Sm and, perhaps, strengthen the use of 223Ra and 
177Lu in the palliative treatment of bone metastases. 
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